<![CDATA[Etentamig Shows Superior Efficacy vs SOC in Relapsed/Refractory Myeloma]]>

Phase 3positiveetentamigPositive

AI Analysis

Summary

Etentamig demonstrated an early overall survival signal in the Phase 3 CERVINO trial for triple-class exposed relapsed/refractory multiple myeloma, showing superior efficacy versus standard of care.

Clinical Trial Data

Phase

Phase 3

Outcome Details

early overall survival signal demonstrated in triple-class exposed relapsed/refractory multiple myeloma patients

Importance:7/10

Sentiment:

0.75

oncologymultiple myelomaPhase 3CERVINO trialrelapsed/refractory

Read the original article

Published by Cancer Network on September 26, 2026 3:00 PM

Read Original